pharmaphorum

APRIL 28, 2022

Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was also strong. Lagevrio (molnupiravir) added $3.2 billion to Merck’s top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda (pembrolizumab) and the Gardasil human papillomavirus (HPV) vaccine range.

Vaccines 105

Vaccines FDA 105

Outsourcing Pharma

APRIL 28, 2022

A leader from the health tech company explains how voice-based technologies could transform monitoring of patients with dementia, Alzheimerâs, and other conditions.

52

52

pharmaphorum

APRIL 28, 2022

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. The Oxford-based company said the financing, led by venture capital arms of Google and Sanofi as well as Northpond Ventures, will be used to bring its portfolio of drug candidates for immunological and rare disease into clinical trials.

105

105

Outsourcing Pharma

APRIL 28, 2022

The addition of the facility in Pennsylvania will help meet the increasing demand for temperature-controlled clinical packaging, storage, and distribution.

Packaging 52

Packaging 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 28, 2022

Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug. The regulator cleared the oral CGRP inhibitor as Vydura for both treatment and prevention of episodic migraine attacks, becoming the first drug to be authorised for both uses in the EU, with a review also underway by the UK authorities.

FDA 98

FDA 98

Pharma Times

APRIL 28, 2022

Women, those who are obese and those on mechanical ventilation are all more likely to suffer from the effects long-term COVID-19

54

54

Pharma Times

APRIL 28, 2022

Long-acting hypertension treatment could provide patients with an injection of medication every six months

46

46

pharmaphorum

APRIL 28, 2022

Rare diseases aren’t as rare as the appellation suggests. For instance, according to the US Government Accountability Office , 30 million Americans have a rare disease, a little less than 10% of the population. But that total represents around 7,000 different diseases, with nothing in common other than their rarity. For pharmaceutical companies, rare diseases present many challenges.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Immunization 59

pharmaphorum

APRIL 28, 2022

Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue. The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery. The industry is now poised to exploit the full therapeutic potential of these vehicles for emerging payloads and extrahepatic delivery.

Vaccines 52

Vaccines 52

pharmaphorum

APRIL 28, 2022

Abbott has joined forces with two other companies to bring an automated insulin delivery (AID) system to people with diabetes in Europe that will monitor blood glucose levels and deliver insulin automatically. The three-way partnership brings Abbott’s FreeStyle Libre 3 wearable sensor with a mobile app developed by Camdiab that communicates with an insulin pump developed by Ypsomed.

Communication 52

Communication 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

APRIL 28, 2022

Denmark’s Novo Nordisk has been almost single-handedly rebuilding the market for drugs to treat obesity over the last few years with its GLP-1 agonist drugs Wegovy and Saxenda, but is now facing a strong challenge from Eli Lilly. The US pharma has just reported top-line results from the first phase 3 trial of its dual GLP-1/GIP agonist tirzepatide as an obesity therapy that back up earlier results showing it can reduce the weight of people with diabetes.

FDA 52

FDA 52